The Center for Discovery and Innovation (CDI) Media Day

The center’s chief scientific officer David Perlin, PhD, provides some insights on the evolution of its antiviral program from its foundation in treating COVID-19 to addressing all pan-coronaviruses.

The Center for Discovery and Innovation’s chief scientific officer David Perlin, PhD, discusses the factors for the growing number of cases and the difficulties in developing such treatments.

David Perlin, PhD, chief scientific officer and executive vice president, the Center for Discovery and Innovation (CDI), talks about his team’s work around developing a diagnostic for Candida auris, and what they are working on in terms of developing antifungals.

The Center for Discovery and Innovation’s Barry Kreiswirth, PhD, discusses this emerging challenge that is ongoing in both the community and healthcare settings, especially around resistant urinary tract infections and how this type of resistance can grow exponentially across strain and pathogens.

Barry Kreiswirth, PhD, discusses how taking an approach similar to that for streptococcal pneumonia can be applied to a potential Klebsiella vaccine.

Veronique Dartois, PhD, and Thomas Dick, PhD, discuss the multidrug resistance associated with non-TB mycobacteria and their research, which focuses on developing a novel version of this class of antibiotics for these infections.